News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Mark Tyson: Urine Tumor DNA Stratifies Recurrence Risk in BCG-Unresponsive NMIBC Treated with Atezolizumab
Mark Tyson/X
May 25, 2025, 05:51

Mark Tyson: Urine Tumor DNA Stratifies Recurrence Risk in BCG-Unresponsive NMIBC Treated with Atezolizumab

Mark Tyson, Associate Professor of Urology at Mayo Clinic in Arizona, posted on X:

“In SWOG 1605, utDNA (UroAmp) predicted response to Atezo in BCG-u bladder cancer. Baseline and 3 month positivity linked to lower CR and EFS.
A step toward biomarkers-driven bladder sparing care.”

Title: Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer.

Authors: Marie-Pier St-Laurent, Parminder Singh, David J. McConkey, M. Scott Lucia, Vadim S. Koshkin, Kelly L. Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Ian M. Thompson Jr, Joshua J. Meeks, Vincent M. Caruso, Ceressa T. Ward, Brian C. Mazzarella, Kevin G. Phillips, Vincent T. Bicocca, Trevor G. Levin, Seth P. Lerner, Peter C. Black

Read The Full Article at European Urology.

Mark Tyson: Urine Tumor DNA Stratifies Recurrence Risk in BCG-Unresponsive NMIBC Treated with Atezolizumab

More posts featuring bladder cancer.

atezolizumab bladder cancer Brian C. Mazzarella cancer Ceressa T. Ward David J. McConkey Ian M. Thompson Jr. Joshua J. Meeks Kelly L. Stratton Kevin G. Phillips M. Scott Lucia Marie-Pier St-Laurent Mark Tyson Melissa Plets NMIBC OncoDaily Oncology Parminder Singh Peter C. Black Rick Bangs Seth P. Lerner Sima P. Porten Trevor G. Levin Trinity J. Bivalacqua Urine Tumor Vadim S Koshkin Vincent M. Caruso Vincent T. Bicocca Wassim Kassouf
Special Coverage
Blog
May 25, 2025, 05:51
Mark Tyson: Urine Tumor DNA Stratifies Recurrence Risk in BCG-Unresponsive NMIBC Treated with Atezolizumab
Blog
May 25, 2025, 05:47
Rebecca Shatsky: Why We Need 1st Line ADC in Metastatic TNBC
Blog
May 25, 2025, 05:41
Vedang Murthy: Abiraterone for High-Risk Prostate Cancer in the PSMA-PET Era - STAMPEDE-Like Cohort Analysis
Blog
May 25, 2025, 05:33
Thor Halfdanarson: Is it Effective and Safe to Use Lu-177 DOTATATE PRRT in Patients With NETs and Extensive Bone Metastases?
Blog
May 25, 2025, 05:14
Bernard Fox: 47 hours of Great Science and Best Discussion at TIMO 2025
Blog
May 25, 2025, 05:02
Olubukola Ayodele: Cancer Isn’t Just a Diagnosis - It’s a Part of Life We All Need to Understand
Career
May 25, 2025, 04:48
Supriya Peshin Started a New Position as a Visiting Resident in Hematology and Oncology at MD Anderson Cancer Center
Blog
May 25, 2025, 02:33
United by Unique: Reflections on the World Cancer Day 2025 Impact Report
Insight
May 24, 2025, 20:22
ESMO-Magnitude of Clinical Benefit Scale version 2.0
Blog
May 24, 2025, 20:10
Miriam Mutebi: Join AORTIC Networking Reception at ASCO 2025 in Chicago
Career
May 24, 2025, 20:00
Ashok Sebastian Komaranchath Has Been Appointed as Consultant and Clinical Lead at Burjeel Cancer Institute, Oman
Insight
May 24, 2025, 19:52
Yan Leyfman: GLP-1 Receptor Agonists may Modestly Reduce the Risk of Developing Certain Cancers